Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray

Hyloris Plans Four New Candidate Product Additions On Average Per Year From 2022

 
• By Rosalind Rei

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Blue-tone 3-D graphic of the side of a human head revealing nasal cavities lit up in orange
Hyloris announces they are developing an intranasal spray for hard-to-treat idiopathic rhinitis • Source: Shutterstock

More from Value Added Medicines

More from Products